Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 17/20 | 0.70 |
| ▸ | NEK2 | P51955 | 4/20 | 0.67 |
| ▸ | CSF1R | P07333 | 3/20 | 0.67 |
| ▸ | KDR | P35968 | 3/20 | 0.67 |
| ▸ | LIMK1 | P53667 | 3/20 | 0.67 |
| ▸ | STK3 | Q13188 | 3/20 | 0.67 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.67 |
| ▸ | BRSK1 | Q8TDC3 | 3/20 | 0.67 |
| ▸ | PLK3 | Q9H4B4 | 3/20 | 0.67 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.67 |
| ▸ | MAP4K5 | Q9Y4K4 | 3/20 | 0.67 |
| ▸ | PLK4 | O00444 | 2/20 | 0.67 |
| ▸ | AURKA | O14965 | 2/20 | 0.67 |
| ▸ | JAK2 | O60674 | 2/20 | 0.67 |
| ▸ | LCK | P06239 | 2/20 | 0.67 |
| ▸ | PIM1 | P11309 | 2/20 | 0.67 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.67 |
| ▸ | SRC | P12931 | 2/20 | 0.67 |
| ▸ | FLT1 | P17948 | 2/20 | 0.67 |
| ▸ | CDK2 | P24941 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5062043 | 0.93 | PLK1 (0.70) | PLK1NEK2CSF1RKDRLIMK1 | |
| SCHEMBL5062408 | 0.92 | PLK1 (0.72) | PLK1NEK2CSF1RKDRLIMK1 | |
| SCHEMBL4404452 | 0.91 | PLK1 (0.80) | PLK1NEK2CSF1RKDRLIMK1 | |
| SCHEMBL5063381 | 0.89 | PLK1 (0.71) | PLK1NEK2CSF1RKDRLIMK1 | |
| Gsk-1030058A SCHEMBL5058261 | 0.88 | PLK1 (0.87) | PLK1NEK2CSF1RKDRLIMK1 | |
| SCHEMBL5062601 | 0.88 | PLK1 (0.66) | PLK1NEK2CSF1RKDRLIMK1 | |
| SCHEMBL5061992 | 0.87 | PLK1 (0.79) | PLK1NEK2CSF1RKDRLIMK1 | |
| SCHEMBL3738464 | 0.87 | PLK1 (0.66) | PLK1NEK2CSF1RKDRLIMK1 | |
| SCHEMBL5058157 | 0.86 | PLK1 (0.72) | PLK1NEK2CSF1RKDRLIMK1 | |
| SCHEMBL3746682 | 0.86 | PLK1 (0.67) | PLK1NEK2CSF1RKDRLIMK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465807-B2 | Process for preparing benzimidazole thiophenes | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-16 | — | — | US | disclosed |
| US-7465807-B2 | Process for preparing benzimidazole thiophenes | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-16 | — | — | US | disclosed |
| US-20080269298-A1 | Benzimidazol-1-YL-thiophene compounds for the treatment of cancer | ANDREWS CLARENCE W | 2008-10-30 | — | — | US | disclosed |
| US-20080269298-A1 | Benzimidazol-1-YL-thiophene compounds for the treatment of cancer | ANDREWS CLARENCE W | 2008-10-30 | — | — | US | disclosed |
| US-20080269298-A1 | Benzimidazol-1-YL-thiophene compounds for the treatment of cancer | ANDREWS CLARENCE W | 2008-10-30 | — | — | US | disclosed |
| US-20070060576-A1 | Process for preparing benzimidazole thiophenes | SMITHKLINE BEECHAM CORPORATION | 2007-03-15 | — | — | US | disclosed |
| US-20070060576-A1 | Process for preparing benzimidazole thiophenes | SMITHKLINE BEECHAM CORPORATION | 2007-03-15 | — | — | US | disclosed |
| US-20060074119-A1 | Thiophene compounds | SMITHKLINE BEECHAM CORPORATION | 2006-04-06 | — | — | US | disclosed |
| EP-1546137-A1 | BENZIMIDAZOL-1-YL-THIOPHENE COMPOUNDS FOR THE TREATMENT OF CANCER | SmithKline Beecham Corporation (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004014899-A1 | THIOPHENE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060576-A1 | Process for preparing benzimidazole thiophenes | CYP3A4, TPMT, TYMP | PLK1 193/4885NEK2 2846/4885CSF1R 4003/4885 |
| US-20060074119-A1 | Thiophene compounds | TPMT, ABCB1, CYP3A5 | PLK1 2123/4885NEK2 4031/4885CSF1R 3595/4885 |
| US-20080269298-A1 | Benzimidazol-1-YL-thiophene compounds for the treatment of cancer | ABCB1, TP53, CCNI | PLK1 130/4885NEK2 636/4885CSF1R 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.